- Current report filing (8-K)
February 04 2010 - 4:38PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
washington,
d.c. 20549
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): February 4,
2010
_______________________
CRYOLIFE,
INC.
(Exact
name of registrant as specified in its charter)
_________________________
|
Florida
|
1-13165
|
59-2417093
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
1655
Roberts Boulevard, N.W., Kennesaw, Georgia 30144
(Address
of principal executive office) (zip code)
Registrant's
telephone number, including area code: (770) 419-3355
_____________________________________________________________
(Former
name or former address, if changed since last report)
_________________________
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction
A.2. below):
|
x
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
q
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Section
8
Other
Events
Item
8.01
Other
Events.
On February 4, 2010, CryoLife, Inc.
(“CryoLife”) mailed an informational letter to the shareholders of Medafor,
Inc. A copy of the letter has also been posted on the CryoLife
website at
www.cryolife.com/medaforoffer
and is attached hereto as Exhibit 99.1.
This filing and the exhibit hereto
are provided for informational purposes only and are not offers to purchase nor
a solicitation of offers to sell shares of Medafor or CryoLife. Subject to
future developments, CryoLife may file a registration statement and/or tender
offer documents and/or proxy statement with the SEC in connection with the
proposed combination. Shareholders should read those filings, and any
other filings made by CryoLife with the SEC in connection with the combination,
as they will contain important information. Those documents, if and
when filed, as well as CryoLife’s other public filings with the SEC, may be
obtained without charge at the SEC’s website at www.sec.gov and at CryoLife’s
website at www.cryolife.com.
Section
9 Financial
Statements and Exhibits
Item
9.01(d) Exhibits.
(a)
Financial Statements.
Not applicable.
(b) Pro
Forma Financial Information.
Not applicable.
(c) Shell
Company Transactions.
Not applicable.
(d)
Exhibits.
|
|
Exhibit Number
|
Description
|
|
|
|
|
|
|
99.1
|
Letter
to Medafor Shareholders dated February 4,
2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
CRYOLIFE,
INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
February 4, 2010
|
By:
|
/s/ D.A.
Lee
|
|
|
|
Name:
|
D.
Ashley Lee
|
|
|
|
Title :
|
Executive
Vice President, Chief
|
|
|
|
|
Operating
Officer and Chief
|
|
|
|
|
Financial
Officer
|
|
CryoLife (NYSE:CRY)
Historical Stock Chart
From Oct 2024 to Nov 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Nov 2023 to Nov 2024
